Spots Global Cancer Trial Database for A Study of TYK-00540 in Adult Patients With Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of TYK-00540 in Adult Patients With Solid Tumors
Official Title: A Phase Ia/Ib, Multicenter, Open-label Study of TYK-00540, Administered Orally in Adult Patients With Locally Advanced/Metastatic Solid Tumors
Study ID: NCT06246071
Interventions
Study Description
Brief Summary: The primary objective of this study is to evaluate the safety and tolerability of TYK-00540, with dose-escalation stage and dose-expansion stage.
Detailed Description: To evaluate dose limiting toxicities (DLT) and determine the maximum tolerated dose (MTD) in subjects with locally advanced or metastatic solid tumors. To investigate the pharmacokinetic profile of TYK-00540 and its metabolites after single then multiple doses of TYK-00540 administered orally once daily. To assess preliminary effectiveness.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: Yes
Locations
Anhui Provincial Hospital, Hefei, , China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
